@morley
yes, that's a good point (regarding the discount rate used to value biological assets).
At the same time, I would be surprised that the market values ATP based on a P/B of 1 x, if they are able to keep their existing level of free cash flow.
If ATP is valued at its book value, it still corresponds to a free cash flow yield of around 29 %.
Ann: 31 December 2021 Interim Financial Report, page-24
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.5¢ |
Change
-0.005(5.00%) |
Mkt cap ! $41.34M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.5¢ | $207.0K | 2.084M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 267100 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 76688 | 3 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| ATP (ASX) Chart |